According to the World Health Organization, in 2020 depression became the second leading cause of disability in the world, after back pain and joint pain. It affects 350 million people in the world, and this is the best proof that depression is a huge problem and, at the same time, an excellent business for pharmaceutical companies that earn millions from the sale of antidepressants.
Lithium compounds have been the most popular mood stabilizers for years. Lithium was first used pharmacologically in the 19th century and is known to have a preventive effect on recurrent depression. After the discovery of the anti-manic effects of lithium, it has been used for over sixty years in the treatment of bipolar disorder in
Lithium salts are one of the oldest currently available psychotropic drugs. Numerous studies have confirmed their value in psychopharmacotherapy, especially when it comes to the treatment and prevention of bipolar disorder (bipolar affective disorder – BPAD, also known as bipolar affective disturbances, previously known as manic depression or cyclophrenia, is characterised by depressive episodes, mania/hypomania
According to the World Health Organization, in 2020 depression will become the second-highest cause of disability in the world behind back and joint pain. There are 350 million sufferers worldwide, of whom already over 2.5 million are in Great Britain alone. This is the best evidence that depression is a huge problem. At the same time, it’s a great business opportunity for pharmaceutical companies that earn hundreds of millions selling anti-depressants.
